Alexion Pharmaceuticals has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to extend the approved indication of Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) to patients who are anti-acetylcholine receptor (AChR) antibody-positive,…
News
News
Researchers Gain Insight Into How Myasthenia Gravis Antibodies Destroy Receptor Vital to Movement
University of Southern California researchers have gained insight into how antibodies connected with a disease known as myasthenia gravis destroy a receptor crucial to movement. Their findings may give scientists clues about how to prevent the disease. The study, “Structural insights into the molecular mechanisms of…
Recent Posts
- Guest Voice: My MG diagnosis led me to become a patient researcher
- Not asking anymore why I developed myasthenia gravis
- Global trial validates self-administered treatment for myasthenia gravis
- Reflecting on decades of rich history that led to our modern MG treatments
- Immune system activity varies across MG subtypes, study finds